Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
1,630,493
-
Share change
-
-759,620
-
Total reported value
-
$6,713,928
-
Put/Call ratio
-
75%
-
Price per share
-
$4.12
-
Number of holders
-
31
-
Value change
-
-$2,460,693
-
Number of buys
-
18
-
Number of sells
-
6
Institutional Holders of BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) as of Q3 2017
As of 30 Sep 2017,
BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) was held by
31 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,630,493 shares.
The largest 10 holders included
VANGUARD GROUP INC, PERCEPTIVE ADVISORS LLC, GEODE CAPITAL MANAGEMENT, LLC, BlackRock Inc., Atlantic Trust Group, LLC, Psagot Investment House Ltd., SUSQUEHANNA INTERNATIONAL GROUP, LLP, NORTHERN TRUST CORP, RENAISSANCE TECHNOLOGIES LLC, and DEUTSCHE BANK AG\.
This page lists
31
institutional shareholders reporting positions in this security
for the Q3 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.